Liver-Kidney Microsome Antibody, IgG
Also known as: LIVER-KID
Use
Liver-Kidney Microsome IgG antibody (anti-LKM), as detected by indirect immunofluorescent antibody (IFA) techniques, may be observed in patients with autoimmune hepatitis type 2 (AIH-2), AIH-2 associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), viral hepatitis C or D, and some forms of drug-induced hepatitis. The presence of anti-LKM-1 (cytochrome P450IID6) IgG antibodies is considered specific for AIH-2.
Special Instructions
Not provided.
Limitations
The IFA does not differentiate among the four types of LKM antibodies (LKM-1, LKM-2, LKM-3, and a fourth type that recognizes CYP1A2 and CYP2A6 antigens). This test was developed by ARUP Laboratories and is not cleared or approved by the FDA. Its performance characteristics have been determined by the laboratory, which operates in a CLIA certified facility.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Liver-Kidney Microsome Antibody, IgG
Antibody
LOINC Codes
- 9838-4 - LKM Ab Titr Ser IF
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.15 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated
Causes for Rejection
Severely hemolyzed or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |
Other tests from different labs that may be relevant